Skip to main content

Clinical Trials › NCT05147220

Active, Not RecruitingPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsored by Novartis Pharmaceuticals

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
1001
Target enrollment
27
U.S. states
Dec 2021
Start date
Oct 2030
Expected completion

Interventions / Treatments

RemibrutinibTeriflunomide

Conditions studied

Relapsing Multiple Sclerosis

Where this trial is running (52 sites)

Florida12 sites
Altamonte Springs · Daytona Beach · Homestead · +9 more
California6 sites
Berkeley · Chula Vista · Glendale · +3 more
Texas5 sites
Dallas · Fort Worth · Houston · +2 more
Arizona2 sites
Phoenix · Tucson
New York2 sites
Lake Success · New York
Charlotte · Raleigh
Pittsburgh · Reading
Wisconsin2 sites
Madison · Neenah
Arkansas1 site
Fort Smith
Colorado1 site
Boulder
Delaware1 site
Newark
Washington D.C.
Illinois1 site
Chicago
Indiana1 site
Fort Wayne
Kansas1 site
Overland Park
Kentucky1 site
Louisville
Maryland1 site
Bethesda
Foxborough
Michigan1 site
Detroit
Missouri1 site
St Louis
Montana1 site
Billings
Neptune City
Ohio1 site
Westerville
Oklahoma1 site
Oklahoma City
Oregon1 site
Portland
Summerville
Virginia1 site
Vienna

MS centers in Florida

Compare treatment centers near a trial site by center type, providers and trials.

View Florida centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play